GH Research PLC
GHRS13.530USD
-0.790-5.52%
Fechamento 11/03, 16:00（ET）Cotações atrasadas em 15 min
812.33MValor de mercado
PerdaP/L TTM
Mais detalhes de GH Research PLC Empresa
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Informações de GH Research PLC
Código da empresaGHRS
Nome da EmpresaGH Research PLC
Data de listagemJun 25, 2021
CEODr. Velichka (Villy) Valcheva, M.D.
Número de funcionários50
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
EndereçoJoshua Dawson House
CidadeDUBLIN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísIreland
Código postalD02 RY95
Telefone35314378334
Site
Código da empresaGHRS
Data de listagemJun 25, 2021
CEODr. Velichka (Villy) Valcheva, M.D.
Executivos da empresa GH Research PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
12.38%
Lynx1 Capital Advisors LLC
10.88%
RTW Investments L.P.
8.93%
Outro
29.68%
Investidores
Investidores
Proporção
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
12.38%
Lynx1 Capital Advisors LLC
10.88%
RTW Investments L.P.
8.93%
Outro
29.68%
Tipos de investidores
Investidores
Proporção
Individual Investor
31.46%
Hedge Fund
22.53%
Investment Advisor
20.54%
Venture Capital
13.30%
Investment Advisor/Hedge Fund
9.66%
Research Firm
4.38%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
79
43.68M
70.41%
-1.27M
2025Q2
81
63.73M
102.74%
+7.16M
2025Q1
80
63.74M
102.77%
+7.17M
2024Q4
74
51.85M
85.10%
-3.62M
2024Q3
76
51.78M
99.44%
-4.46M
2024Q2
78
51.68M
99.26%
-4.52M
2024Q1
77
50.90M
97.75%
-4.57M
2023Q4
73
50.91M
97.80%
-2.89M
2023Q3
74
50.54M
97.15%
-4.64M
2023Q2
82
51.15M
98.33%
-4.53M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Schonharting (Florian)
14.82M
23.9%
--
--
Dec 31, 2024
BVF Partners L.P.
8.83M
14.23%
--
--
Jun 30, 2025
RA Capital Management, LP
7.68M
12.38%
+732.05K
+10.54%
Jun 30, 2025
Lynx1 Capital Advisors LLC
6.75M
10.88%
+303.01K
+4.70%
Jun 30, 2025
RTW Investments L.P.
5.54M
8.93%
+40.69K
+0.74%
Jun 30, 2025
Fidelity Management & Research Company LLC
5.09M
8.21%
+842.57K
+19.83%
Jun 30, 2025
Terwey (Theis)
4.69M
7.57%
-1.50M
-24.16%
Jun 30, 2025
Cormorant Asset Management, LP
2.01M
3.24%
--
--
Jun 30, 2025
Deep Track Capital LP
2.00M
3.22%
--
--
Jun 30, 2025
TD Securities, Inc.
1.97M
3.17%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
AdvisorShares Psychedelics ETF
5.62%
iShares MSCI Ireland ETF
0.88%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
SPDR S&P International Small Cap ETF
0.02%
ALPS Medical Breakthroughs ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
AdvisorShares Psychedelics ETF
Proporção5.62%
iShares MSCI Ireland ETF
Proporção0.88%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.8%
SPDR S&P International Small Cap ETF
Proporção0.02%
ALPS Medical Breakthroughs ETF
Proporção0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
